ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO2052

Increased Autoantibodies Against Ro/SS-A, CENP-B, and La/SS-B in Patients with Kidney Allograft Antibody-Mediated Rejection

Session Information

Category: Transplantation

  • 1901 Transplantation: Basic

Authors

  • Clotet Freixas, Sergi, University Health Network, Toronto, Ontario, Canada
  • Kotlyar, Max, University Health Network, Toronto, Ontario, Canada
  • McEvoy, Caitriona M., University Health Network, Toronto, Ontario, Canada
  • Pastrello, Chiara, University Health Network, Toronto, Ontario, Canada
  • Rodriguez Ramirez, Sonia, University Health Network, Toronto, Ontario, Canada
  • Farkona, Sofia, University Health Network, Toronto, Ontario, Canada
  • Cardinal, Heloise, Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CHUM), Montreal, Quebec, Canada
  • Dieudé, Mélanie, Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CHUM), Montreal, Quebec, Canada
  • Hebert, Marie-Josee, Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CHUM), Montreal, Quebec, Canada
  • Li, Yanhong, University Health Network, Toronto, Ontario, Canada
  • John, Rohan, University Health Network, Toronto, Ontario, Canada
  • Chruscinski, Andrzej, University Health Network, Toronto, Ontario, Canada
  • Konvalinka, Ana, University Health Network, Toronto, Ontario, Canada
Background

Antibody-mediated rejection (AMR) causes >50% of late kidney graft losses. In addition to anti-HLA donor-specific antibodies (DSA), antibodies against non-HLA antigens are also linked to AMR. Identifying key non-HLA antibodies will improve our understanding of AMR.

Methods

We analyzed non-HLA antibodies in sera from 80 kidney transplant patients with AMR, mixed rejection, acute cellular rejection (ACR), or acute tubular necrosis (ATN). IgM and IgG antibodies against 134 non-HLA antigens were measured in serum samples collected pre-transplant or at the time of diagnosis.

Results

Fifteen non-HLA antibodies were significantly increased (p<0.05) in AMR and mixed rejection compared to ACR or ATN pre-transplant, and seven at diagnosis. AMR and mixed cases showed significantly increased pre-transplant levels of IgG anti-Ro/SS-A and anti-CENP-B, compared to ACR. Together with IgM anti-CENP-B and anti-La/SS-B, these antibodies were significantly increased in AMR/mixed rejection at diagnosis. Increased IgG anti-Ro/SS-A, IgG anti-CENP-B and IgM anti-La/SS-B were associated with the presence of microvascular lesions and class-II DSA (p<0.05). Significant increases in IgG anti-Ro/SS-A and IgM anti-CENP-B antibodies in AMR/mixed rejection compared to ACR were reproduced in an external cohort of 60 kidney transplant patients.

Conclusion

This is the first study implicating autoantibodies anti-Ro/SS-A and anti-CENP-B in AMR. These antibodies may participate in the crosstalk between autoimmunity and alloimmunity in kidney AMR.